Oncofoetal insulin receptor isoform A marks the tumour endothelium; an underestimated pathway during tumour angiogenesis and angiostatic treatment

Nowak-Sliwinska, Patrycja; van Beijnum, Judy R; Huijbers, Elisabeth J M; Gasull, Paula C; Mans, Laurie; Bex, Axel; Griffioen, Arjan W

doi:10.1038/s41416-018-0347-8

Scientific article

English

Oncofoetal insulin receptor isoform A marks the tumour endothelium; an underestimated pathway during tumour angiogenesis and angiostatic treatment

ContributorsNowak-Sliwinska, Patrycja; van Beijnum, Judy R; Huijbers, Elisabeth J M; Gasull, Paula C; Mans, Laurie; Bex, Axel; Griffioen, Arjan W

Published inBritish Journal of Cancer, vol. 120, no. 2, p. 218-228

Publication date2019

Abstract

In a genomic screen for determinants of the tumour vasculature, we identified insulin receptor (INSR) to mark the tumour endothelium. As a functional role for insulin/INSR in cancer has been suggested and markers of the tumour endothelium may be attractive therapeutic targets, we investigated the role of INSR in angiogenesis.

Keywords

Animals
Antigens, CD/genetics
Cell Proliferation/genetics
Chick Embryo
Chorioallantoic Membrane/metabolism/pathology
Disease Models, Animal
Endothelium/metabolism/pathology
Female
Gene Knockdown Techniques
Genome, Human/genetics
Human Umbilical Vein Endothelial Cells
Humans
Insulin/genetics/metabolism
Kidney Neoplasms/genetics/pathology
Male
Mice
Neovascularization, Pathologic/genetics/pathology
Protein Isoforms/genetics
RNA, Small Interfering/genetics
Receptor, Insulin/genetics
Tumor Cells, Cultured

Affiliation entities

Faculté des sciences / Section des sciences pharmaceutiques

Research groups

Pharmacologie moléculaire

Citation (ISO format)

NOWAK-SLIWINSKA, Patrycja et al. Oncofoetal insulin receptor isoform A marks the tumour endothelium; an underestimated pathway during tumour angiogenesis and angiostatic treatment. In: British Journal of Cancer, 2019, vol. 120, n° 2, p. 218–228. doi: 10.1038/s41416-018-0347-8